학술논문

Evaluating the Patient-Reported Outcomes Measurement Information System scales in acute intermittent porphyria.
Document Type
article
Source
Genetics in medicine : official journal of the American College of Medical Genetics. 22(3)
Subject
Humans
Porphyria
Acute Intermittent
Fatigue
Heme
Severity of Illness Index
Longitudinal Studies
Depression
Anxiety
Quality of Life
Adolescent
Adult
Aged
Middle Aged
Female
Male
Young Adult
Sleep Wake Disorders
Patient Reported Outcome Measures
PROMIS
acute intermittent porphyria
patient-reported outcomes
quality of life
Genetics
Clinical Sciences
Genetics & Heredity
Language
Abstract
PurposeAcute intermittent porphyria (AIP) is a rare inborn error of heme biosynthesis characterized by life-threatening acute attacks. Few studies have assessed quality of life (QoL) in AIP and those that have had small sample sizes and used tools that may not have captured important domains.MethodsBaseline data from the Porphyrias Consortium's Longitudinal Study were obtained for 259 patients, including detailed disease and medical history data, and the following Patient-Reported Outcomes Measurement Information System (PROMIS) scales: anxiety, depression, pain interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. Relationships between PROMIS scores and clinical and biochemical AIP features were explored.ResultsPROMIS scores were significantly worse than the general population across all domains, except depression. Each domain discriminated well between asymptomatic and symptomatic patients with symptomatic patients having worse scores. Many important clinical variables like symptom frequency were significantly associated with domain scores in univariate analyses, showing responsiveness of the scales, specifically pain interference and fatigue. However, most regression models only explained ~20% of the variability observed in domain scores.ConclusionPain interference and fatigue were the most responsive scales in measuring QoL in this AIP cohort. Future studies should assess whether these scales capture longitudinal disease progression and treatment response.